Table 4

Multivariate Cox model (DFS) including interaction of uPA/PAI-1 with adjuvant treatment in primary breast cancer (n = 3376)a

Analysis was stratified by center: 46 patients were censored before the first event in the stratum, 1301 events total. First stage of analysis included established prognostic factors, uPA/PAI-1, adjuvant radiotherapy, adjuvant chemotherapy, and adjuvant endocrine therapy. Second stage included interactions (chemo- and endocrine therapy with uPA/PAI-1; chemotherapy with endocrine therapy) and involved lymph nodes with uPA/PAI-1.

Significant factorsbCoding for interpretation of βFinal model
PβHR (95% CI)
Involved lymph nodesFractional rank:<0.0012.47
 1 node vs. node-negative2.2 (2.0–2.3)c
 4 nodes vs. node-negative3.7 (3.3–4.2)c
 10 nodes vs. node-negative5.3 (4.5–6.2)c
AgeSquared fractional rank<0.0011.293.65 (1.73–7.70)d
Fractional rank<0.001−1.940.14 (0.07–0.31)d
Tumor stageRest (1) vs. pT1 (0)<0.0010.301.35 (1.19–1.54)
Rest (1) vs. pT1/pT2 (0)0.0080.221.24 (1.06–1.46)
PgRFractional rank<0.001−0.420.66 (0.55–0.80)d
uPA/PAI-1High (1) vs. low (0)<0.0010.702.01 (1.77–2.28)
Adjuvant chemotherapyYes (1) vs. no (0)<0.001−0.370.69 (0.56–0.85)
Adjuvant endocrine therapyYes (1) vs. no (0)<0.001−0.380.68 (0.56–0.82)
Interaction, chemotherapy × uPA/PAI-1Both 1 vs. either or both 00.003−0.380.68 (0.53–0.88)
  • a Forty-five of 3424 were excluded because of incomplete information on the number of involved nodes; 3 of 3424 were excluded because of missing information on adjuvant chemotherapy (see Table 1 <$REFLINK> ).

  • b Coding of variables as reported in “Materials and Methods.”

  • c HR for patients with 1, 4, and 10 positive nodes compared with node negative patients; CI is approximate because of fractional ranks.

  • d Hazard for fractional rank = 1 compared with fractional rank = 0.